The presence of two fragments of Ozurdex implants in the vitreous body

Cover Page

Cite item

Full Text

Abstract

Aim – to present a clinical case of the remnant of the Ozurdex implant in the vitreous body.

Material and methods. One patient was under observation. During the preoperative examination and surgical treatment, two fragments of the Ozurdex implant were found in the vitreous body.

Results. The presented clinical case shows that the remnants of the Ozurdex intravitreal implant can persist for 10 months or more after injection. This fact is clinically important for assessing the therapeutic effect and choice of further treatment tactics for a patient.

About the authors

Mikhail A. Artemov

Samara Regional Clinical Ophthalmological Hospital named after T.I. Eroshevsky

Author for correspondence.
Email: artemov1989@gmail.com
ORCID iD: 0000-0002-4992-1957

Ophthalmologist of the Ophthalmological Microsurgery Department №4

Russian Federation, Samara

Ilya S. Kazakov

Samara Regional Clinical Ophthalmological Hospital named after T.I. Eroshevsky

Email: dr-cz@yandex.ru
ORCID iD: 0000-0003-3589-8618

Head of the Ophthalmological Microsurgery Department №4

Russian Federation, Samara

Andrey V. Zolotarev

Samara Regional Clinical Ophthalmological Hospital named after T.I. Eroshevsky; Samara State Medical University

Email: a.v.zolotarev@samsmu.ru
ORCID iD: 0000-0002-9107-5221

PhD, Professor, Chief Physician, Head of the Department of Ophthalmology of SamSMU

Russian Federation, Samara; Samara

References

  1. Haller JA, Bandello F, Belfort R, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117:1134-1146.e1133. doi: 10.1016/j.ophtha.2010.03.032
  2. Boyer DS, Yoon YH, Belfort R, et al. Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014; 121:1904-1914. doi: 10.1016/j.ophtha.2014.04.024
  3. Yalcinbayir O, Caliskan E, Ucan Gunduz G, et al. Efficacy of dexamethasone implants in uveitic macular edema in Cases with Behcet Disease. Ophthalmologica. 2019;241(4):190-194. doi: 10.1159/000490674
  4. Sun YJ, Lin Ch-H, Wu M-R, et al. An intravitreal implant injection method for sustained drug delivery into mouse eyes. Cell Rep Methods. 2021;1(8):100-125. doi: 10.1016/j.crmeth.2021.100125
  5. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80-86. doi: 10.1167/iovs.10-5285
  6. Mazzarella S, Mateo C, Freixes S, et al. Effect of intravitreal injection of dexamethasone 0.7 mg (Ozurdex(R)) on intraocular pressure in patients with macular edema. Ophthalmic Res. 2015;54:143-149. doi: 10.1159/000438759
  7. Lowder C, Belfort R, Lightman S, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129:545-553. doi: 10.1001/archophthalmol.2010.339
  8. Maturi RK, Pollack A, Uy HS, et al. Intraocular pressure in patients with diabetic macular edema treated with dexamethasone intravitreal implant in the 3-year MEAD Study. Retina. 2016;36:1143-1152. doi: 10.1097/IAE.0000000000001004
  9. Haller JA, Bandello F, Belfort R, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453-2460. doi: 10.1016/j.ophtha.2011.05.014
  10. Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res. 2010;27:2043-2053. doi: 10.1007/s11095-010-0159-x
  11. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3:1377-1397. doi: 10.3390/polym3031377
  12. Yasukawa T, Ogura Y, Kimura H, et al. Drug delivery from ocular implants. Expert Opin Drug Deliv. 2006;3:261-273. doi: 10.1517/17425247.3.2.261
  13. Kim JT, Lee SH, Choi SU. Persistent remnants of dexametasone intravitreal implant (Ozurdex). Retina. 2020;40(11):2226-2231. doi: 10.1097/IAE.0000000000002778

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Figure 1. OCT of the macular zone.

Download (1MB)
Indexing metadata
3. Figure 2. Fragments of two Ozurdex implants.

Download (536KB)
Indexing metadata

Copyright (c) 2022 Artemov M.A., Kazakov I.S., Zolotarev A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).